Andrew Huberman· PhD
And, again, it all boils back down to the selectivity of psilocybin to bind that serotonin to a receptor.
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
And, again, it all boils back down to the selectivity of psilocybin to bind that serotonin to a receptor.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
And so my point is, what's new? OK. Maybe it's a bit new and people are now developing direct 2A agonists rather than indirect through a serotonin releaser like the selective serotonin reuptake inhibitors, the SSRIs like Lexapro.